Aelis Farma SA (AELIS.PA)
- Previous Close
1.2350 - Open
1.2350 - Bid --
- Ask --
- Day's Range
1.2250 - 1.2650 - 52 Week Range
1.0000 - 13.3000 - Volume
3,169 - Avg. Volume
45,029 - Market Cap (intraday)
16.75M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
www.aelisfarma.comRecent News: AELIS.PA
View MorePerformance Overview: AELIS.PA
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AELIS.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AELIS.PA
View MoreValuation Measures
Market Cap
16.82M
Enterprise Value
9.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.02
Price/Book (mrq)
1.69
Enterprise Value/Revenue
1.68
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-134.05%
Return on Assets (ttm)
-21.03%
Return on Equity (ttm)
-63.95%
Revenue (ttm)
5.56M
Net Income Avi to Common (ttm)
-7.46M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
14.05M
Total Debt/Equity (mrq)
60.14%
Levered Free Cash Flow (ttm)
-9.32M